Letermovir in pregnancy versus valaciclovir for fetal CMV
Treatments studied
Part of Genetic & congenital, Infections, Women’s health & pregnancy clinical trials.
This trial tests whether letermovir can treat a baby’s early (first-trimester) congenital CMV infection in pregnancy, compared with the standard drug valaciclovir. The goal is to reduce serious effects from CMV while monitoring safety and pregnancy outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and at least 18 years old
- You were infected with CMV early in pregnancy (first trimester)
- Between 15 and 28 weeks, testing from amniotic fluid shows CMV (positive CMV PCR)
- Your ultrasound does not show certain severe brain changes (like enlarged ventricles, hydrocephalus, or very small head size)
- You can give consent and are able and willing to attend study visits and tests
- You have health insurance coverage through a social security plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Hear when a new Pregnant Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.